Form 4: Avita Medical CEO James Corbett Awarded Stock Options Following Shareholder Approval
SEC Form 4
Avita Medical's CEO, James Corbett, received 350,000 stock options after shareholder approval, vesting annually over three years.
Summary
- James Corbett, CEO of Avita Medical, was granted 350,000 stock options.
- The grant was approved by the Board of Directors on January 3, 2024, with an exercise price of $12.64 per share, matching the closing price on that date.
- Shareholder approval was obtained on June 5, 2024, which finalized the grant.
- The options vest in three equal annual installments starting 12 months after the grant date of January 3, 2024.
- The options expire on January 3, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices and aligns management interests with shareholders. There are no immediate negative implications.
Positives
- The equity grant aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The CEO's compensation is now further tied to the company's performance through these stock options.
Industry Context
Stock option grants are a common practice in the biotech industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to align executive incentives with shareholder value.
- The vesting schedule of three years is also typical, encouraging long-term commitment.
Stakeholder Impact
- Shareholders: The grant aligns the CEO's interests with shareholder value.
- Employees: The grant may boost employee morale by demonstrating confidence in the company's leadership.
- CEO: The grant provides a financial incentive for the CEO to improve company performance.
Key Dates
| Date | Description |
|---|---|
| January 3, 2024 | Board of Directors approved the grant of stock options and effective grant date. |
| June 5, 2024 | Shareholder approval obtained for the stock option grant. |
| January 3, 2025 | First vesting date for the stock options (12 months following the grant date). |
| January 3, 2034 | Expiration date of the stock options. |
| June 6, 2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.